Author:
Carracedo Sarah,Palmero Ana,Saenz Carla
Abstract
AbstractIn the context of a public health emergency it is imperative to conduct research studies that will produce evidence rapidly while upholding ethical standards. The Ebola and Zika outbreaks highlighted the importance of devising agile processes for ethics review in emergencies, and international research ethics guidelines stress the duty to depart from standard processes for ethics review in emergency circumstances. However, before the COVID-19 pandemic it was not entirely clear what emergency procedures should look like. An additional challenge is that while the same substantive ethical standards apply in emergency and non-emergency settings, deciding what these standards entail in the specific circumstances of a pandemic may be difficult. During the COVID-19 pandemic, challenges included identifying thresholds of social and scientific value, along with duties towards research participants, given the absence of therapeutic options; assessing continually changing risk–benefit profiles of studies, given rapidly emerging new evidence; developing appropriate informed consent processes, given lockdown scenarios; and even addressing the ethics of offering unproven interventions outside research settings. Additional issues raised during epidemics include devising feasible and meaningful community engagement strategies, mechanisms to ensure fairness in the distribution of the benefits that may result from research, and equitable and effective data-sharing plans that will inform pandemic response. Learning from these procedural and substantive challenges encountered in the ethics review of COVID-19 research is important for enhancing ethics preparedness for future emergencies. It can also potentially contribute to improving the ethics review of research in non-emergency circumstances. The seven cases in this chapter highlight ethical issues associated with ethics approval of multi-centre studies in pandemics, the need for careful consideration of the social and scientific value of research and challenges encountered when interventions are being transitioned from research to rollout, and issues that can arise when existing regulations and policies may limit capacities to appropriately adapt research to pandemic contexts.
Publisher
Springer International Publishing
Reference18 articles.
1. Carracedo, S., A. Palmero, M. Neil, A. Hasan-Granier, C. Saenz, and L. Reveiz. 2020. The landscape of COVID-19 clinical trials in Latin America and the Caribbean: Assessment and challenges. Revista Panamericana de Salud Publica 44: e177. https://doi.org/10.26633/RPSP.2020.177.
2. CIOMS. 2016. International ethical guidelines for health-related research involving humans. Geneva: Council for International Organizations of Medical Sciences. https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf.
3. Herper, M., and E. Riglin. 2020. Data show panic and dis-organization dominate the study of Covid-19 drugs. STAT News, July 6. https://www.statnews.com/2020/07/06/data-show-panic-and-disorganization-dominate-the-study-of-covid-19-drugs/.
4. ICMR. 2020. National guidelines for ethics committees reviewing biomedical research during COVID-19 pandemic. New Delhi: Indian Council of Medical Research. https://ethics.ncdirindia.org//asset/pdf/EC_Guidance_COVID19.pdf.
5. London, A.J. 2021. Self-defeating codes of medical ethics and how to fix them: Failures in COVID-19 response and beyond. American Journal of Bioethics 21(1): 4–13. https://doi.org/10.1080/15265161.2020.1845854.